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The present study aimed to assess the quality and risks involved in the consumption of psychoactive herbal products (PHs) that
are available through informal commerce in the city of Diadema, SP, Brazil. Methods of ethnography were used to conduct the
fieldwork during which four dealers were selected to record the collection, handling, packaging, types of PHs marketed, and their
therapeutic purposes. In addition, lots of the PHs selected were purchased from the dealers and analyzed using microbiology and
pharmacognosy techniques. 217 PHs were recorded and categorized into two main groups: stimulants (67%) and depressants (27%)
of the central nervous system; sixteen of them were selected, and their 52 lots were acquired.The deficiencies observed in handling
and packaging these lots by dealers were confirmed by microbiological analysis; 80.8% of them presented risk according to the
indicators defined by the Brazilian Pharmacopoeia. The pharmacognostic analysis confirmed the authenticity of only 9 to 16 PHs
analyzed. In addition, descriptions of contraindications, adverse reactions, and drug interactions were found in the literature for
the PHs. The results of this study allow the observation of the priorities for the sanitary adequacy of the popular trade of herbs.
1. Introduction
There are several legal definitions for herbal products (HPs).
In this study, HPs involve the following definitions: herbal
drugs, which aremainly whole, fragmented, or broken plants,
parts of plants, algae, fungi, or lichen, in an unprocessed state,
usually in dried form but sometimes fresh; herbal teas which
consist exclusively of one or more herbal drugs intended for
oral aqueous preparations by means of decoction, infusion,
or maceration [1]. According to Delay et al. [2], psychoactive
herbs are those that act by modifying physiological and
behavioral aspects of human beings, such as cognitive ability,
patterns of thought, and humor. According to the physiolog-
ical changes that the plant causes, the HPs may be classified
as stimulants, depressants, or hallucinogens.
Although the use of medicinal plants and/or HP is part of
humanhistory, few researchers have been dedicated to under-
standing the complications and risks that may arise from the
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use of such “medicine,” including Barnes et al. [3] and Elvin-
Lewis [4].
In Brazil and many other countries, there is informal
trade of HPs in the streets without quality control, sanitary
inspection, and scientific evidence. The most prominent
problems in thismarket suggest the use of wrong species, sub-
stitutions (sometimes intentional), problems with labels, and
microbial contamination, leading to inconsistency in quality.
Naturally, the lack of quality control leads to uncertainty in
the safety and efficacy of the plant’s therapeutic use as a raw
material, resulting in risks to consumers [5, 6].
Accordingly, this study is aimed at interdisciplinary
research about the quality and potential risks involved in the
consumption of psychoactive herbal products (PHs) available
in the informal commerce in the city of Diadema, SP, Brazil.
2. Methodology
This project was approved by the Ethics Committee (CEP) of
the Universidade Federal de Sa˜o Paulo (CEP 1672/07). The
PHs’ dealers who agreed to participate in the study signed a
consent form.
2.1. Ethnopharmacological Survey. Fieldwork was conducted
by one of the authors (Soares, JAR), from November 2006
to July 2009 in Diadema, located 17 km from Sa˜o Paulo.
For this purpose, we used the following methods and tech-
niques of ethnography: participant observation, informal
and semistructured interviews and notes in a field diary
[7, 8] allowing the selection of four respondents (PHs’
dealers), and the recorded data obtained by applying two
data sheets: ethnopharmacological data (including questions
about commercialized PHs, forms of preparation, route
of administration, doses, contraindications, obtaining, han-
dling, and packaging) and socioeconomic data (including
information on how the dealers learned details of the trade
in PHs, age, place of birth, sex, education, and income). A
sample of the PHs indicated was selected; lots of them were
acquired from each of the interviewees and analyzed using
pharmacognosy and microbiology techniques. Since not all
respondents marketed all of these PHs, the number of lots of
each PH analyzed varies from 1 to 4. Thus, for PHs that were
marketed by all dealers, four lots were analyzed. Available in
our earlier publication [9] are the criteria for the selection of
these samples and details about the methodology used in this
ethnopharmacological survey.
2.2. Analysis of Quality
2.2.1. Pharmacognostic Analysis
Morphoanatomical. The lots were analyzed to verify their
authenticity according to the pharmacopoeias or the litera-
ture. In addition, we observed whether there was contami-
nation or adulteration by macroscopic characterization with
the naked eye and stereoscopicmagnifying glass. Histological
sections from plant organs were prepared as previously
described and documented [23].
2.2.2. Chromatographic Profile. The powdered HPs in a
grinder of knives and hammers were extracted with suitable
solvents to the group of substances to be evaluated. Then,
thin-layer chromatographic analyses, using a substance or
reference sample extract, were performed [24, 25]. The dis-
approved lots in the morphoanatomical characters were not
submitted to chromatographic analyses. Star anise, Matri-
caria flower, St. Johnwort, lemon balm,Ginkgo, ginseng, lime
flower, and valerian were analyzed according to the European
Pharmacopoeia [26]. While passion fruit, guarana, mara-
puama, clove vine, and mulungu were analyzed according
to the Brazilian Pharmacopoeia [25, 27]. Finally, reference
substances/extracts were used in the analyses of node of dog
[28], catuaba [29–31], and Brazilian ginseng [32, 33]; these
analyses were performed according to the literature.
2.2.3. Microbiological Analysis. The lots were analyzed to
verify their possible microbial contamination. They were
evaluated for the load of bacteria and fungi present
and the presence of microorganism indicators of risk for
oral administration—Salmonella spp., Escherichia coli, Pseu-
domonas aeruginosa, Bacillus cereus, Enterobacter spp., Can-
dida albicans, Aspergillus flavus, and A. parasiticus—as in
Brazilian Pharmacopoeia [34]. In addition, we observed
the potential of mycoflora isolated to produce aflatoxins,
ochratoxin A, and citrinin.
Microbiological analyses were performed as described in
official compendia [6, 25]. Those analyses for the enumera-
tion of heterotrophic bacteria and fungi used the technique
of sowing depth; those for the enumeration of E. coli and
other enterobacteria used the technique of multiple pipes;
and those for the isolation and identification of bacteria used
selective culture media and differential staining techniques
and biochemical tests.
We performed the isolation of fungi in potato dextrose
agar, incubated at 26 ± 1∘C for 10 days to identify the
taxonomic schemes of Rapper and Fennel [35] and Pitt [36],
for observation of morphological and micromorphological
features.
To evaluate the toxigenic potential of Aspergillus and
Penicillium isolated from the lots, we conducted inoculation
in coconut agar pH 7.0 + 0.1 (to evaluate the potential to
produce aflatoxins and ochratoxin A) and coco agar pH
5.0 + 0,1 (to evaluate the potential to produce citrinin),
incubated at 26 ± 1∘C for 10 days [37]. After incubation,
the colonies were transferred to glass bottles with a large
opening, which were weighed and soaked in chloroform at a
rate of 3.0 mL per 1.0 g of material. The mash was kept under
stirring for 30 minutes in a horizontal mechanical shaker and
then filtered with filter paper. The filtrate was collected in
a test tube and evaporated in a water bath at 80∘C under a
hood allocated to CSA. Mycotoxins were detected by thin
layer chromatography, as described by Soares and Rodriguez-
Amaya [38] and confirmation of the chemical identity of the
mycotoxins was performed by appropriate techniques.
2.3. Analysis of Potential Risks. To facilitate the analysis of
the potential risk of the consumption of PHs investigated in
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this study, Table 1 was organized containing ethnopharmaco-
logical,microbiological, and pharmacognostic data regarding
the 16 PHs selected. A literature review was conducted to
verify the existence of adverse reactions, drug interactions,
and contraindications for these PHs.The databases consulted
included the following: Micromedex, FDA Poisonous Plant
Database, Scopus, SciELO, PubMed, Capes, Google Scholar,
FDA Consumer, Science Direct, and SpringerLink. We used
the following key words for the literature review (“Adverse
reaction” OR “Adverse events” OR “Side effects” OR “Phar-
macovigilance” OR “Toxicology” OR “Hospitalization” OR
“Death” AND scientific name of the PH); we chose to restrict
the bibliographic survey only for human trials; in the absence
of data we utilized some preclinical trials to improve the
discussion.
3. Results and Discussion
3.1. Socioeconomic Data. All dealers selected are men and
originating from rural areas of the northeast Brazil. They
declared themselves evangelical practitioners and reported
that it was in their place of origin, within the family group
and community, where they started learning about medicinal
plants and applicants in their localities. Today many factors
such as books, internet, television, and even the customers
are sources of knowledge. Working time (trade PHs) showed
large variations, between six and 54 years. Apparently the
average customer was not proportional to the time/work
experience ofmarketer, getting between 10 and 50 clients/day,
according to what is declared.The declared gross income was
between $150.00 and $2.750,00 and the net income between
$58.00 and $2.125,00. All had low education and did not
complete elementary school.
3.2. Trade of PHs in Diadema. Deficiencies were observed
in the acquisition, handling, and packaging of these PHs.
All dealers buy the PHs exclusively from wholesalers in the
central region of Sa˜o Paulo, without worrying about their
authenticity.They buy and sell the PHs based on their popular
names. It was observed that in most cases the dealers do
not know the importance of their scientific identification.
Many are purchased in powder form, which facilitates further
tampering. The replacement of the stock is performed on
average every two weeks. The PHs are bought in bulk and
fractionated for sale at the place of business or at home. Two
of the respondents, after fractioning, use a custom label on
the packaging, while others simply keep the original bags in
the tent open and sell drugs by spoonfuls or portions (“one
hand”) packed in a paper bag.The storage of PHs is itself one
of themost critical points, as dealers do not have a system that
allows operation of the stock to preserve the HPs quality and
validity and to avoid mixing of lots.
3.3. Profile of PHs. The average value of PHs was $1.50
a unit (the bag), but this can vary up to $15.00. During
the interviews, 217 PHs were cataloged and classified into
three groups: stimulants (67%), depressants (27%), and
stimulants and depressants (6%) of central nervous system.
Thus, the terms quoted by dealers are as follows: “calm,”
“sedation,” “epilepsy,” “hysteria,” “anguish,” and “relaxing”
which were categorized as depressants, while the uses “tonic,”
“impotence,” “aphrodisiacs,” and “to improve memory” were
categorized as stimulants. The more frequent preparation
methods were decoction (43%) and infusion (25%). The
leaves and flowers (soft tissue) were used in the form of
infusion, and the hard parts such as skins, seeds, and roots
were used in the form of decoction. All PHs in powder
form had the indication to be solubilized in water, milk,
or juice, and in some cases it was recommended to put
the powder in the food. The route of administration was
always oral.The dosage and administration of tea (howmany
times a day) varied mainly based on the age of the client
and on disease severity. Additionally, the dealers showed
strong resistance to prescribing teas for children andpregnant
women.They prescribe half the dose for children. Babies can
hardly swallow the HPs, except for matricaria flower and
fennel prescribed for colic. Some studies have been carried
out in Brazil with healers that sell HPs in streets and open air
[39–45]. They show a great diversity in the acquisition forms
and preparation of the HPs.
The Brazilian media, in general, perpetuates the popular
belief that medicinal plants and their derivatives are at low
risk or are exempt from risks in the treatment of diseases.
With the development of pharmacovigilance, we note that in
recent years it has been remarkable, especially in scientific
publications, that errors in identification of plant species,
fraud, tampering, contamination, heavy metals, and interac-
tions with drugs have caused previously little known adverse
events [46–49].
Sixteen of 217 PHs were selected and their 52 lots
were analyzed microbiologically and pharmacognostically
(Table 1). These analyses allowed us to verify the authenticity
of 28 (53.5%) of 52 lots, that is, 9 PHs (star anise: 2 lots,
matricaria flower: 3, clove vine: 3; ginkgo: 4, guarana: 4,
passion fruit: 4; marapuama: 4; lime flower: 2; valerian: 2).
From the 28 lots, 12 had foreign matter, and 9 had contam-
ination by other plant organs in the upper limit permitted
by the pharmacopoeias. They are matricaria flower: 1 lot;
ginkgo: 2; guarana: 3; passion fruit: 3; three lots were found to
contain presence of insects (matricaria flower: 1 lot; ginkgo:
1; and guarana: 1). The remaining 24 lots, regarding 7 PHs
confronted the pharmacopoeial monographs or, literature by
the popular name handwritten on the packaging, were disap-
proved by noncoincidence with the PH described (catuaba:
4 lots; St. John wort: 3; ginseng: 4; jatobá: 3; lemon balm: 2;
mulungu: 4; node of dog: 4). One problem that hinders the
identification of PHs, originating from various locations and
even import, is the use of different vernacular names for each
particular plant in different regions.
The name “catuaba” includes several plants, among
which are Anemopaegma arvense (Vell.) Stellfeld & JF Souza
(Bignoniaceae), Erythroxylum vacciniifolium Mart., E. sub-
racemosum Turcz (Erythroxylaceae), Tetragastris catuaba
Soares da Cunha (Burseraceae), and Trichilia catigua A. Juss.
(Meliaceae) [50–52]. Although the Brazilian Pharmacopoeia
first edition has certificated the subterranean organs of
Anemopaegmamirandum (Cham.)Mart. ex DC. as “catuaba,”
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they were found in local market samples of the bark of
Trichilia catigua, a fact previously reported by Marques [29].
The bark of their stems in combination with other plant
extracts has been used in energy drinks.The species has been
little studied in some animal trials, which suggest antinoci-
ceptive and antidepressant activity. The antidepressant activ-
ity was associated with modulation of the serotonergic and
dopaminergic systems [13, 53, 54].
The mechanism of antidepressant activity of T. catigua
has been suggested as similar to that of Hypericum perfo-
ratum L. (Hypericaceae), a plant known as St. John wort,
which has indications for mild to moderate depression. The
samples acquired in the trade did not correspond to the
morphological characteristics of H. perforatum, which may
correspond to the species Ageratum conyzoides L. (Aster-
aceae), also popularly called St. John wort in Brazil, but
with anti-inflammatory activity [55]. The lots of ginseng did
not coincide with the species described in pharmacopoeia
(Panax ginseng C.A.Mey.-Araliaceae) nor with Pfaffia pan-
iculata (Mart.) Kuntze-Amaranthaceae, known as “Brazilian
ginseng” [33]. For the history ofmarketing in Brazil and chro-
matographic profile these samples correspond in fact to the
roots ofPfaffia glomerata (Martius)Kuntze (Amaranthaceae),
a species known as “Brazilian ginseng” or “suma” and more
easily found in trade [32].
The “jatobá” is not registered in pharmacopoeias, but
Oliveira et al. [56] describe the morphology and anatomy of
its fruit as the parts used as a medicine. The lots collected
consisted of stem bark, which has led to its reproof.
The materials called “mulungu” consisted of stem bark
and part of the wood, of Erythrina species, which are com-
mon in the country. The description present in the pharma-
copoeia [27] for E. mulungu Mart. ex Benth. (E. verna Vell.)
(Fabaceae) is brief, consisting only of characteristics common
to the genre such as princkly and ornate bark, phloem with
sclerenchyma, crystals in the phloem parenchyma, broad and
conspicuous rays with starch, and fibers arranged in loose
tangencial groups. Although the morphoanatomical study
showed characters common to Erythrina species, the com-
parative thin layer chromatographic profile using authentic
sample ofE.mulungu and a reference compound (hesperidin)
appeared distinct [24]. No similarities were found between
them, suggesting that different species of the genus are
marketed under the vernacular name.
Although it was expected that the lots acquired as “node
of dog” coincided with the underground organs of Heterop-
terys aphrodisiaca O. Mach. (Malpighiaceae), it was found
that in the tents selected for the study this herb is replaced
by the weed Vernonia cognata Less. (Asteraceae), known as
“fish-bakes purple” and “purple cambarazinho” [28, 57]. H.
aphrodisiaca is employed as an adaptogen, in the bottled form
[58], and shows a protective effect in the germinal epithelium
of the male rat reproductive system [59]. No adverse effects
were observed during its consumption as infusion [60].
Microbiological parameters, which are considered risk
indicators defined by the Brazilian Pharmacopoeia [34],
showed that 42 of the 52 lots analyzed were at odds, that
is, 80.8%. Although the official compendia [6, 25] recom-
mend the absence of Aspergillus flavus and A. parasiticus in
products intended for oral administration because of concern
for possible contamination by aflatoxins, we verified the pres-
ence of other potentiallymycotoxigenic fungal isolates among
eight genera detected (Aspergillus ochraceus, Aspergillus niger,
otherAspergillus, Penicillium citrinum, other Penicillium, and
Trichoderma). This occurrence is in accordance with several
studies onHPs [61–67]. In assessing the potential toxigenicity
of the isolates ofAspergillus and Penicillium in the production
of aflatoxins (B1, B2, G1, and G2), ochratoxin A and citrinin
revealed that only four lots containing isolates of A. flavus
showed the ability to produce aflatoxins, three of which
demonstrated the capacity to produce only aflatoxin B1 (clove
vine: 1 lot; marapuama: 1; and lime flower: 1) while one lot
of St. John wort has the potential to produce aflatoxins B1
and B2. However, even though some isolated fungi presented
mycotoxigenic potential, it is not possible to presuppose that
there are mycotoxins in the product, since the expression of
this toxicogenic potential depends on favorable conditions as
regards temperature and humidity [61, 66, 67].
3.4. Potential Risks. For the analysis of potential risks in-
volved in consumption of PHs in the present study, we add the
data posted above resulting from our pharmacognostic and
microbiological analyses and data from the literature found
for the nine PHs that had their authentication confirmed in
this study (Table 1). For each PH, we obtained data on adverse
reactions, contraindications, or interactions, indicating a
need for medical monitoring of their consumption. These
analyses indicate possible risks in their consumption because
the patient who seeks such PHs rarely communicates with his
or her doctors about their simultaneous usage with allopathic
medicines, ignoring drug interactions. Moreover, because
they are sick, some patients may be immunosuppressed,
so the use of drugs contaminated by certain fungi and
bacteria can lead to worsening of the disease and may even
favor the expression of others. Still, most of these PHs are
contraindicated during pregnancy, according to the data
(Table 1), which may cause risks to both pregnancy and
breastfeeding. Additionally, the lack of effective regulatory
actions and populational studies on their usemakes it difficult
to estimate the health risks associated with those products as
regards the presence of microorganisms, and mycotoxins.
3.5. Future Aspects. It is estimated that about 80% of the
world population have already used herbal products. This is
due to the increase in the popularity of the products in the
United States, Europe, and other parts of theworld.Moreover,
they have been successfully used throughout the history of
Eastern cultures.
However, the popular use of those plants requires some
care [68, 69], especially in countries where its purchase is
free. Consequently, the WHO has recently classified herbal
products as a target for pharmacovigilance, encouraging
member states to strengthen supervision and regulation of
those products, also reinforcing the fact that it is a priority
to identify the risks associated with their use. Additionally, it
warns that the difficulty to access adequate information and
the specific technical requirements can hinder the process
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[70]. Nevertheless, since supervision of those products lacks
quality, they bare not considered a priority, in spite of their
negative impact on public health [71].
In Brazil, the government is making many efforts to
control the marketing of herbal medicine [72] which has re-
ceived greater relevance with the publication of the Policy
and theNational ProgramonMedicinal Plants [73].However,
there is still much to be done to establish a standard of ideal
quality. According to American Botanical Council [74] this
problem also occurs in many other countries, but important
initiatives can be taken in a joint effort between the three
sectors involved (government, business, and civil society), as
occurs in the USA today.
4. Conclusions
The results obtained by the different analysis presented here
indicate the risk of consumption of the 16 PHs analyzed in
light of their contamination by species of microorganism risk
indicators (15 PHs) which do not match the species listed
in pharmacopoeias (7 PHs) and their contamination with
foreign materials (4 PHs). In addition to the problems in the
present study,we also found an extensive repertoire of adverse
reactions described in scientific literature for the nine PHs
that had their pharmacognostic authentication confirmed by
our analysis.
We conclude that the acquired PHs require improvements
in the packaging, labeling, and quality suitable for the
proposed purpose of local traders. These data emphasize the
need for sanitary inspection and guidance to local traders to
observe the quality of the HPs to be ingested by consumers.
With recent economic interest in medicinal plants, it is
necessary to investigate the nature of adulteration. Diversion
of quality is an economic loss to the consumer. We must
create a framework conducive to the necessary fitness of the
industry, and we should evaluate our ability to monitor the
quality of these HPs and support training programs.
Moreover, there is an urgent need to measure the impact
of folk medicine with the use of PHs in cases of adverse
reactions, drug interactions and worsening of disease, and
the development of more scientific research to define the
risks/benefits involved in their consumption.
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